GlassScriptPhysician profile
Ayisha Gani
NPI 1629050638
$2,775.90
in general payments reported to CMS, 2019-2025
32 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $494 · 2021: $289 · 2022: $332 · 2023: $463 · 2024: $448 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $319.66 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $268.72 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $260.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $211.18 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $162.86 | 2019-2021 | |
| Lilly USA, LLC | $143.36 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $117.48 | 2020-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.74 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.81 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $76.23 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $68.15 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $62.25 | 2025 | Gemtesa |
| Antares Pharma, INC. | $62.23 | 2020-2021 | |
| Abbott Laboratories | $56.00 | 2021-2024 | Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.56 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $49.94 | 2020 | |
| Corcept Therapeutics | $46.36 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $33.76 | 2020-2021 | |
| Lundbeck LLC | $32.13 | 2024 | Rexulti |
| Edwards Lifesciences Corporation | $30.00 | 2025 | Sapien 3 Ultra Resilia |
| Dexcom, INC. | $29.31 | 2024 | Dexcom G6 Transmitter |
| Medtronic USA, INC. | $24.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.24 | 2024 | |
| Biotronik Nro, INC. | $19.81 | 2024 | Prospera |
| Biohaven Pharmaceuticals, INC. | $19.11 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.02 | 2023 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $17.72 | 2024 | Nuzyra |
| Inspire Medical Systems, INC. | $17.18 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $16.71 | 2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $14.84 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayisha Gani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.